Notice NOT-MD-21-025 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-21-048 from the NIH Guide for Grants and Contracts. The National Cancer Institutes (NCI) Cancer Systems Biology Consortium (CSBC, https://csbconsortium.org/) supports the application of systems biology approaches to cancer research and includes U01 Research Projects and, through this FOA, U54 Research Centers. These multi-project Centers should address challenges in basic cancer biology that would benefit from a coordinated systems biology approach and should coalesce around a well-defined overarching scientific theme pursued through two or three research projects. The research projects should be driven by a specific hypothesis and incorporate iterative cycles of quantitative experimentation, analysis, modeling, and validation in a disease-relevant context. Centers will include an interdisciplinary research team including quantitative and cancer biology expertise, administrative management, optional shared resource cores, and an Outreach core that support the overall Center research theme. Each Center will make sharing interoperable datasets and community accessible tools a priority with the support of a multi-consortium U24 Coordinating Center (being solicited under RFA-CA-21-049), actively collaborate within and outside the consortium, and support a welcoming and diverse research community at the Center and Consortium level.

The multi-omic analysis methods we develop will be paired with machine learning to understand changes in metabolism associated with disease.
From Medical College of Wisconsin - Tue, 27 Jul 2021 21:14:13 GMT - View all Milwaukee, WI jobs

Funding Opportunity RFA-MH-21-237 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) intends to support a Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE) that will be composed of four components to establish respectively (1) a common sequencing data processing pipeline, (2) a common imaging data processing pipeline, (3) a comprehensive brain cell knowledge base, and (4) an engaging and outreach component to coordinate the research within and beyond BICAN. The overall goals of CUBIE are to (i) enable the exploration of large-scale brain cell atlas data and knowledge, and inspire research in brain function and disorders; and (ii) ensure research rigor and data reproducibility by making the data to be findable, accessible, interoperable, and reusable, and the process transparent. An application is expected to propose only one of the above four respective components.

Funding Opportunity RFA-MH-21-236 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) intends to support a group of Specialized Collaboratories that will adopt scalable technology platforms and streamlined sampling strategies and assay cascade to create comprehensive and highly granular brain cell atlases in human, non-human primates, and mouse, in coordination and collaboration with other BICAN projects. In particular, the Specialized Collaboratories are expected to complement the Comprehensive Centers in BICAN with distinct capabilities, competencies, and research aims. The overarching goal of the BICAN is to build reference brain cell atlases that will be widely used throughout the research community, providing a molecular and anatomical foundational framework for the study of brain function and disorders.

Funding Opportunity RFA-MH-21-235 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) intends to support a group of large-scale Comprehensive Centers that will adopt scalable technology platforms and streamlined sampling strategies and assay cascade to create comprehensive and highly granular brain cell atlases of human and non-human primates with an emphasis on human. The Centers are expected to characterize all brain cell types (neurons, glia, and other non-neuronal cells) at high-resolution. The overarching goal of the BICAN is to build reference brain cell atlases that will be widely used throughout the research community, providing a molecular and anatomical foundational framework for the study of brain function and disorders.

Funding Opportunity RFA-CA-21-050 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support canine clinical studies using immunotherapeutic agents and novel drug combinations together with laboratory correlative studies that seek to characterize and understand the cellular and molecular mechanisms that determine anti-tumor responses (or non-responses) in pet dogs with spontaneous tumors. The goal is to create a network of laboratories and canine clinical trial sites. The proposed clinical studies must include therapeutic modulation of the tumor microenvironment (TME) or must elicit direct immune-mediated destruction of cancer. Priority attributes include: combinations of immunotherapy/TME-modulating therapy with radiation therapy or other therapies (e.g., targeted therapies, chemotherapies or other immunotherapies); adoptive immune cell therapies such as CAR T-cell therapies or NK cell therapies; studies including longitudinal biopsy; and studies including tumor DNA sequencing and transcriptomics in pet dogs treated with immunotherapeutic agents. Within the network, awardees are expected to share therapeutic agents, specimens, and laboratory and clinical protocols in order to standardize and validate data generated. A companion funding opportunity will support a coordinating center that will aid in the development, standardization, harmonization, and conduct of the clinical and laboratory studies, as well as data management and statistical support across the funded U01 sites (see U24 award supported under companion RFA-CA-21-051).

Funding Opportunity RFA-CA-21-051 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support a coordinating center to facilitate coordination across the Canine Cancer Immunotherapy Network (K9CIN; see U01 awards supported under companion RFA-CA-21-050) that will conduct immunotherapy clinical trials in pet dogs with spontaneous tumors and perform laboratory correlative studies associated with the clinical trials. The network will include a representative from the NCI Comparative Oncology Program (COP) of the NCI's Center for Cancer Research as an integral component. The awardee will contribute to the administration of a steering committee of required expertise--both inside and outside the U01 network, including the PD/PIs of the U01s, representatives of the COP, and the NCI Project Collaborators --to ensure that the goals of the network are accomplished. The Coordinating Center will have several responsibilities, including, but not limited to providing administrative support to the K9CIN: development and standardization of clinical protocols and correlative assays; implementation of clinical studies in immunotherapy and combination agents including accrual to the trials; providing statistical support; facilitating sharing of agents, specimens, and data; harmonization of clinical data; and submission of clinical and correlative data to the Integrated Canine Data Commons.

Notice NOT-AR-21-027 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-21-033 from the NIH Guide for Grants and Contracts. The NINDS Materials to Enhance Training in Experimental Rigor (METER) UE5 will support curriculum development in the form of innovative educational materials that will be incorporated into a new cutting-edge online resource that aims to promote awareness, understanding, and practice of fundamental principles of rigorous biomedical research for researchers and other scientists in various career stages and learning environments. This UE5 FOA runs in parallel with a companion UC2 FOA that solicits applications for the NINDS center for Creating an Educational Nexus for Training in Experimental Rigor (CENTER), described in detail in RFA-NS-21-009.

Funding Opportunity RFA-NS-21-009 from the NIH Guide for Grants and Contracts. This is one of two Funding Opportunity Announcements (FOAs) that together aim to facilitate teaching of fundamental principles of rigorous biomedical research by developing an online educational resource for use by a broad range of researchers in an array of learning environments. The purpose of this FOA is to support the establishment of a center for Creating an Educational Nexus for Training in Experimental Rigor (CENTER), which will build, evaluate, and disseminate a user-friendly, harmonized, and openly accessible educational resource to promote awareness, understanding, and utilization of the principles of rigorous biomedical research.

Urging self-care doesn’t fix unrealistic work expectations, our Experimental Error columnist writes

Competitive with benefits, subject to skills and experience: The Francis Crick Institute: The lab is studying signalling pathways that control the biology of B and T lymphocytes. London (Greater) (GB)

Negotiable: SRG: An opportunity for an experienced Molecular Biologist to join an established organisation working at the forefront of drug discovery. Greater Manchester, England

Notice NOT-OD-21-153 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-21-042 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the U01 PDAC Stromal Reprogramming Consortium (PSRC) RFA-CA-21-041. The purpose of this FOA is to create a U24 Coordinating and Data Management Center (CDMC) that will support the overall coordination and research aims of the PSRC Research Projects. This FOA solicits U24 cooperative agreement applications from appropriate multidisciplinary groups that can assemble the appropriate infrastructure to facilitate and implement the administrative, outreach, collaborative and data management activities of the PSRC. This FOA is open to any qualified applicant.

Funding Opportunity RFA-CA-21-041 from the NIH Guide for Grants and Contracts. Cut and paste

£32,780-£41,093: Wellcome Sanger Institute: The Parts Lab is seeking a postdoctoral fellow to focus on identifying new drug targets for neurodegenerative disorders. Cambridge United Kingdom

Applicants with experience in microbiome research and/or possessing bioinformatics skills desired. The Research Specialist will work closely with the principal…
From University of Wisconsin–Madison - Fri, 23 Jul 2021 18:57:47 GMT - View all Madison, WI jobs

Notice NOT-CA-21-062 from the NIH Guide for Grants and Contracts